![Outcomes of Continuation vs Discontinuation of Adalimumab Therapy During Third Trimester of Pregnancy in Inflammatory Bowel Disease - ScienceDirect Outcomes of Continuation vs Discontinuation of Adalimumab Therapy During Third Trimester of Pregnancy in Inflammatory Bowel Disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2772572322000620-gr1.jpg)
Outcomes of Continuation vs Discontinuation of Adalimumab Therapy During Third Trimester of Pregnancy in Inflammatory Bowel Disease - ScienceDirect
![IJMS | Free Full-Text | The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding IJMS | Free Full-Text | The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding](https://www.mdpi.com/ijms/ijms-22-02922/article_deploy/html/images/ijms-22-02922-g001a.png)
IJMS | Free Full-Text | The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding
![These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA ® (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002 These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA ® (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=humira-09.jpg&id=770190)
These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA ® (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002
![Frontiers | Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road Frontiers | Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road](https://www.frontiersin.org/files/Articles/621247/fphar-12-621247-HTML-r1/image_m/fphar-12-621247-g001.jpg)
Frontiers | Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road
![These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA ® (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002 These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA ® (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=humira---cordavis-co-branded-22.jpg&id=771346)
These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA ® (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002
![Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis - Hart - 2022 - United European Gastroenterology Journal - Wiley Online Library Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis - Hart - 2022 - United European Gastroenterology Journal - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/6e8a012d-934e-417f-b3fc-e7f8d4bd0b21/ueg212236-fig-0001-m.jpg)